Redefining adjuvant chemotherapy in patients with stage III colon cancer: X-ACT trial

Expert Review of Anticancer Therapy

Volumn 8, Issue 4, 2008, Pages 547-551

  Glen, Hilary ^a,b   Cassidy, Jim ^b,c  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^c Centre for Oncology and Applied Pharmacology   (United Kingdom)

Author keywords

5 fluorouracil; Adjuvant treatment; Capecitabine; Colon cancer; X ACT trial

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; UFT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ALOPECIA; ARTICLE; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL PROTOCOL; CLINICAL TRIAL; COLON CANCER; DIARRHEA; DISEASE FREE SURVIVAL; DRUG APPROVAL; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PATIENT SELECTION; QUALITY OF LIFE; SEPSIS; STOMATITIS; TREATMENT DURATION; ADOLESCENT; ADULT; AGED; COLON TUMOR; COMPARATIVE STUDY; COST; DRUG ADMINISTRATION; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; SURVIVAL RATE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; COSTS AND COST ANALYSIS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INJECTIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; SURVIVAL RATE;

EID: 43049157907     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.4.547     Document Type: Article

References (27)

1. Twelves C, Wong A, Nowacki MP et al. Capecitabine as adjuvant treatment for stage III colon cancer. N. Engl. J. Med. 352(26), 2696-2704 (2005).
2. Van Cutsem E, Dicato M, Wils J et al. Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, Ireland, 2001). Eur. J. Cancer 38(11), 1429-1436 (2002).
3. Moertel CG, Fleming TR, Macdonald JS et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N. Engl. J. Med. 322(6), 352-358 (1990).
4. Moertel CG, Fleming TR, Macdonald JS et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes'B2 colon cancer. J. Clin. Oncol. 13(12), 2936-2943 (1995).
5. No authors listed. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 345(8955), 939-944 (1995).
6. O'Connell MJ, Mailliard JA, Kahn MJ et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J. Clin. Oncol. 15(1), 246-250 (1997).
7. Wolmark N, Rockette H, Fisher B et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J. Clin. Oncol. 11(10), 1879-1887 (1993).
8. Porschen R, Bermann A, Loffler T et al. Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01. J. Clin. Oncol. 19(6), 1787-1794 (2001).
9. Miwa M, Ura M, Nishida M et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer 34 (8), 1274-1281 (1998).
10. Twelves C. Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, Phase III trials. Eur. J. Cancer 38(Suppl.2), 15-20 (2002).
11. Cassidy J, Twelves C, Van Cutsem E et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann. Oncol. 13(4), 566-575 (2002).
12. Borner MM, Schoffski P, de Wit R et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur. J. Cancer 38(3), 349-358 (2002).
13. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J. Clin. Oncol. 15(1), 110-115 (1997).
14. Payne SA. A study of quality of life in cancer patients receiving palliative chemotherapy. Soc. Sci. Med. 35(12), 1505-1509 (1992).
15. Scheithauer W, McKendrick J, Begbie S et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann. Oncol. 14(12), 1735-1743 (2003).
16. Twelves C, Scheithauer W, McKendrick J et al. 5-year overall survival update from the X-ACT trial of capecitabine vs 5-FU/LV as adjuvant treatment for stage III colon cancer. Eur. J. Cancer Suppl. 5(6) (2007) (Abstract 1LB).
17. Cassidy J, Douillard JY, Twelves C et al. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes'C colon cancer: the X-ACT trial. Br. J. Cancer 94(8), 1122-1129 (2006).
18. Garrison L, Patel KK, Sengupta N et al. The cost-effectiveness of capecitabine as adjuvant oral chemotherapy for Dukes'C cancer. Presented at: International Society for Pharmacoeconomics and Outcomes Research Annual International Meeting. Washington, DC, USA, 15-18 May 2005 (Poster PCN7).
19. Di Costanzo F, Sobrero A, Twelves C et al. Capecitabine vs bolus 5-FU/LV as adjuvant chemotherapy for patients with Dukes'C colon cancer: economic evaluation in an Italian hospital setting. J. Clin. Oncol. 24 (Suppl. 18) (2006) (Abstract 13518).
20. Dufour PR, Douillard J, Ychou M et al. Cost-effectiveness of adjuvant capecitabine, Mayo Clinic and de Gramont regimens for stage III colon cancer in the French setting. J. Clin. Oncol. 24(Suppl. 18) (2006) (Abstract 13506).
21. Cortes P, Douillard J-Y, Twelves C et al. Pharmacoeconomic analysis of capecitabine in the adjuvant setting. Preliminary cost analysis in Portugal based on results from the X-ACT trial comparing capecitabine with 5-FU/LV in patients with Dukes'C colon cancer. Presented at: Portuguese Conference on Health Economy 2005. Coimbra, Portugal, 24-26 Nov 2005 (Poster).
22. Virik K, Skedgel C, Younis T. Economic evaluation of adjuvant chemotherapy in stage III (SIII) colon cancer: capecitabine versus 5FU/ LV. J. Clin. Oncol. 24(Suppl. 18) (2006) (Abstract 6046).
23. Lembersky BC, Wieand HS, Petrelli NJ et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J. Clin. Oncol. 24(13), 2059-2064 (2006).
24. Andre T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med. 350(23), 2343-2351 (2004).
25. Kuebler JP, Wieand HS, O'Connell MJ et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J. Clin. Oncol. 25(16), 2198-2204 (2007).
26. Schmoll HJ, Cartwright T, Tabernero J et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J. Clin. Oncol. 25(1), 102-109 (2007).
27. Cassidy J, Clarke S, Rubio ED et al. First efficacy and safety results from XELOX-1/NO16966, a randomised 2×2 factorial phase III trial of XELOX vs. FOLFOX4 + bevacizumab or placebo in first-line metastatic colorectal cancer (MCRC). Ann. Oncol. 17(Suppl. 9), (2006) (Abstract LBA3)